keyword
MENU ▼
Read by QxMD icon Read
search

psoriasis and cardiovascular disease

keyword
https://www.readbyqxmd.com/read/29787813/vascular-involvement-in-axial-spondyloarthropathies
#1
Clément Prati, Céline Demougeot, Xavier Guillot, Maxime Sondag, Frank Verhoeven, Daniel Wendling
Ankylosing spondylitis (AS) is a chronic inflammatory joint disease that involves the entheses, causing inflammatory pain and functional impairments. Patients may experience extraarticular manifestations such as uveitis, psoriasis, and inflammatory bowel disease. These, together with the increased risk of cardiovascular disease and osteoporosis and the development of spinal fusion, are the main determinants of adverse disease outcomes. As with many systemic inflammatory diseases, AS is associated with excess cardiovascular mortality due to increased risks of myocardial infarction, stroke, and venous thromboembolism...
May 19, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29779304/non-invasive-measurements-to-stratify-cardiovascular-disease-risk-in-psoriasis-patients
#2
Philippa Dickison, Jonathan J Peek, Grace Swain, Saxon D Smith
BACKGROUND AND OBJECTIVES: Psoriasis is associated with cardiovascular disease (CVD) risk factors and mortality. The aims of this study were to identify CVD risk in patients with psoriasis, and to determine their awareness of the comorbidities. METHOD: Patients with psoriasis and controls had their inter-arm blood pressure, weight, height and waist circumference measured at their routine clinic appointment. Those with psoriasis also completed a survey regarding awareness of the comorbidities...
May 2018: Australian journal of general practice
https://www.readbyqxmd.com/read/29776990/effect-of-2-psoriasis-treatments-on-vascular-inflammation-and-novel-inflammatory-cardiovascular-biomarkers-a-randomized-placebo-controlled-trial
#3
Nehal N Mehta, Daniel B Shin, Aditya A Joshi, Amit K Dey, April W Armstrong, Kristina Callis Duffin, Zelma Chiesa Fuxench, Charlotte L Harrington, Rebecca A Hubbard, Robert E Kalb, Alan Menter, Daniel J Rader, Muredach P Reilly, Eric L Simpson, Junko Takeshita, Drew A Torigian, Thomas J Werner, Andrea B Troxel, Stephen K Tyring, Suzette Baez Vanderbeek, Abby S Van Voorhees, Martin P Playford, Mark A Ahlman, Abass Alavi, Joel M Gelfand
BACKGROUND: Psoriasis is a chronic inflammatory disease associated with dyslipidemia, cardiovascular events, and mortality. We aimed to assess and compare the effect of treatment of moderate-to-severe psoriasis with adalimumab or phototherapy on vascular inflammation and cardiovascular biomarkers. METHODS AND RESULTS: Randomized, double-blind, trial of adalimumab, phototherapy, and placebo (1:1:1) for 12 weeks, with crossover to adalimumab for 52 weeks total. Outcomes included vascular inflammation by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography and biomarkers of inflammation, insulin resistance, and lipoproteins...
June 2018: Circulation. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29772435/aliskiren-preclinical-evidence-for-the-treatment-of-hyperproliferative-skin-disorders
#4
Priscila Lúcia Pawloski, Camila Guimarães Moreira, Cintia Delai Silva Horinouchi, Daniel Fernandes, Luiz Renato Olchanheski, Willian Machado, Daniela Almeida Cabrini, Michele Dietrich, Kátia Paludo, Michel Fleith Otuki
Psoriasis is a complex inflammatory and hyperproliferative skin disease. The pathogenesis and mechanisms involved are not completely understood, which makes treatment a difficult issue. Angiotensin II, the most active peptide of the renin-angiotensin system, seems to be involved in processes related to psoriasis pathogenesis, such as inflammation and cell proliferation. The aim of this study was to investigate the influence of renin inhibition on inflammation parameters and keratinocyte proliferation in a mouse model of chronic skin inflammation induced by croton oil...
May 14, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29742274/safety-of-tildrakizumab-for-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-three-randomised-controlled-trials
#5
A Blauvelt, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaci, Q Li, N Cichanowitz, S Green, C La Rosa
BACKGROUND: Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated. OBJECTIVES: Safety/tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from 3 randomised controlled trials for moderate-to-severe psoriasis. METHODS: Data pools for the placebo-controlled (up to 16 weeks) and full-trial periods (up to 64 weeks) were analysed (N=2081). RESULTS: In the placebo-controlled period, frequencies of treatment-emergent adverse events (TEAEs; range=47...
May 9, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29733939/ethnic-differences-and-comorbidities-of-909-prurigo-nodularis-patients
#6
Emily Boozalis, Olive Tang, Shivani Patel, Yevgeniy R Semenov, Manuel P Pereira, Sonja Stander, Sewon Kang, Shawn G Kwatra
BACKGROUND: Prurigo Nodularis (PN) is a poorly understood, understudied pruritic dermatosis that reduces quality of life. OBJECTIVE: To characterize the demographics and comorbidities associated with PN. METHODS: Cross-sectional study of patients ≥ 18 years old seen at the Johns Hopkins Health System (JHHS) between 12/6/2012-12/6/2017. RESULTS: Over the last five years, 909 patients with PN were seen at JHHS. African-American patients were 3...
May 4, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29730187/identification-of-proresolving-and-inflammatory-lipid-mediators-in-human-psoriasis
#7
Alexander V Sorokin, Paul C Norris, Justin T English, Amit K Dey, Abhishek Chaturvedi, Yvonne Baumer, Joanna Silverman, Martin P Playford, Charles N Serhan, Nehal N Mehta
BACKGROUND: Psoriasis (PSO) is an immune-mediated inflammatory disease associated with metabolic and cardiovascular comorbidities. It is now known that resolution of inflammation is an active process locally controlled by specialized proresolving mediators (SPMs), named resolvins (Rvs), protectins, and maresins. OBJECTIVE: It is unknown whether these potent lipid mediators (LMs) are involved in PSO pathophysiology and if the skin and blood have disease-specific SPMs phenotype profiles...
April 6, 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29723384/prevalence-of-smoking-alcohol-consumption-and-metabolic-syndrome-in-patients-with-psoriasis
#8
Esra Adışen, Selda Uzun, Funda Erduran, Mehmet Ali Gürer
BACKGROUND: Coexistence of obesity, hypertension, insulin resistance and dyslipidemia is defined as metabolic syndrome (MBS), which is among the important risk indicators for cardiovascular diseases, diabetes and stroke. Smoking and alcohol consumption are the other factors which lead to an increase in the risk of cardiovascular disease. OBJECTIVE: To investigate the prevalence of metabolic syndrome, smoking and alcohol consumption in psoriasis patients and the relationship between disease severity and these factors...
March 2018: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/29719939/psoriasis-and-risk-of-myocardial-infarction-before-and-during-an-era-with-biological-therapy-a-population-based-follow-up-study
#9
M Z Leisner, J Lindorff Riis, R Gniadecki, L Iversen, M Olsen
BACKGROUND: Attention towards cardiovascular disease prevention in patients with moderate to severe psoriasis increased with the introduction of biological therapy. OBJECTIVE: To determine the risk of myocardial infarction (MI) following hospital diagnosed psoriasis compared with the general population, in eras before and following the introduction of biological therapy. METHODS: We conducted a cohort study in Denmark utilizing nationwide prospectively collected data from population-based registries...
May 2, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29718018/do-psoriasis-patients-engage-in-vigorous-physical-activity
#10
Mina Amin, Erica B Lee, Tina Bhutani, Jashin J Wu
Psoriasis is associated with cardiovascular risk factors and myocardial infarction, but regular physical activity is known to decrease the risk of coronary heart disease. We performed a systematic review of PubMed articles indexed for MEDLINE as well as articles in the Embase database and Cochrane Library using the search terms psoriasis and physical activity to determine the likelihood of psoriasis patients to engage in vigorous physical activity. A total of 353 nonduplicate articles were identified, and of 4 relevant studies, one provided sufficient data and was included in our review...
March 2018: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/29705839/stress-and-systemic-inflammation-yin-yang-dynamics-in-health-and-diseases
#11
Qing Yan
Studies in psychoneuroimmunology (PNI) would provide better insights into the "whole mind-body system." Systems biology models of the complex adaptive systems (CASs), such as a conceptual framework of "Yin-Yang dynamics," may be helpful for identifying systems-based biomarkers and targets for more effective prevention and treatment. The disturbances in the Yin-Yang dynamical balance may result in stress, inflammation, and various disorders including insomnia, Alzheimer's disease, obesity, diabetes, cardiovascular diseases, skin disorders, and cancer...
2018: Methods in Molecular Biology
https://www.readbyqxmd.com/read/29694270/higher-incidence-rates-of-comorbidities-in-patients-with-psoriatic-arthritis-compared-with-the-general-population-using-u-s-administrative-claims-data
#12
Jeffrey Kaine, Xue Song, Gilwan Kim, Peter Hur, Jacqueline B Palmer
BACKGROUND: Psoriatic arthritis (PsA) is associated with multiple comorbid conditions, including cardiovascular (CV) comorbidities that impose a considerable burden on patients. Effective management of PsA requires an understanding of comorbidity profiles. OBJECTIVE: To compare the frequency and incidence rates of comorbidities and hospitalizations among newly diagnosed PsA patients and a matched general population without PsA, using large national claims databases in the United States...
April 25, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29683293/psoriasis-as-a-cardiovascular-risk-factor-updates-and-algorithmic-approach
#13
Emanuele Cozzani, Gianmarco Rosa, Martina Burlando, Aurora Parodi
Although psoriasis is predominantly a chronic inflammatory skin disorder, it has been known to be associated with cardiovascular disease. Patients with psoriasis, particularly with moderate to severe forms, present an increased rate of cardiovascular mortality, myocardial infarction and stroke. However the pathophysiology of the relationship between psoriasis and cardiovascular risk and comorbidities has not yet completely known. Chronic inflammation may be considered a solid link between psoriasis and related cardiovascular events...
April 19, 2018: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29675020/systemic-inflammation-and-cardiovascular-comorbidity-in-psoriasis-patients-causes-and-consequences
#14
REVIEW
Wolf-Henning Boehncke
Psoriasis is a common inflammatory skin disease characterized by the appearance of red scaly plaques that can affect any part of the body. High prevalence, chronicity, disfiguration, disability, and associated comorbidity make it a challenge for clinicians of multiple specialties. Likewise, its complex pathogenesis, comprising inflammation, hyperproliferation, and angioneogenesis, intrigues numerous scientific disciplines, namely, immunology. From a clinical perspective, the severity of psoriasis is highlighted by its increased mortality, with cardiovascular diseases contributing the highest excess risk...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29664028/dyslipidaemia-oxidative-stress-in-patients-of-psoriasis-emerging-cardiovascular-risk-factors
#15
Kumari Asha, Archana Singal, Suman Bala Sharma, Vinod Kumar Arora, Amitesh Aggarwal
Background & objectives: Psoriasis is a recurrent hyper-proliferative skin disease which is often associated with free radical generation, abnormal lipid metabolism and increased inflammatory secretion that induce cardiovascular risk in these patients. The present study was intended to evaluate serum lipids, lipoprotein and oxidants-antioxidants status and to establish their relationship with atherogenic risk markers [oxidized low-density lipoprotein (oxLDL) and high-sensitivity C-reactive protein (hsCRP)] in patients with psoriasis...
December 2017: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/29662733/psoriasis-and-cardiovascular-diseases-a-literature-review-to-determine-the-causal-relationship
#16
REVIEW
Shanu Jindal, Nitin Jindal
Psoriasis is a chronic, complex autoimmune disease characterized by erythematous, scaly patches over extensor aspects of skin and is associated with joint involvement in about one-third of patients. An association between psoriasis and cardiovascular diseases (CVD) has been a topic of dilemma, and many studies have shown an increased risk of cardiovascular morbidity in patients with psoriasis. There is increasing evidence that psoriasis is associated with higher risk of CVD and increased prevalence of cardiovascular risk factors, as compared with the general population...
February 15, 2018: Curēus
https://www.readbyqxmd.com/read/29656791/cardiovascular-risk-factors-predicting-cardiac-events-are-different-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-psoriasis
#17
Roxanne Cooksey, Sinead Brophy, Jonathan Kennedy, Fabiola Fernandez Gutierrez, Tim Pickles, Ruth Davies, Vincent Piguet, Ernest Choy
OBJECTIVES: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk factor. However, the contribution of traditional cardiovascular risk factors (such as obesity and hyperlipidaemia) compared to inflammation is uncertain in psoriatic arthritis (PsA) and RA...
March 17, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29614138/common-and-not-so-common-comorbidities-of-psoriasis
#18
M Alan Menter, April W Armstrong, Kenneth B Gordon, Jashin J Wu
Plaque psoriasis is increasingly recognized as a multisystemic disease whose most common comorbidities include psoriatic arthritis, cardiovascular disease, metabolic syndrome, overweight/obesity, inflammatory bowel disease, and depression. The presence of such comorbidities affects the therapeutic choices for clinicians. Patients often visit dermatologists more frequently than they do other clinicians, so it is incumbent upon dermatologists to recognize and address early signs of psoriatic comorbidities to prevent further deterioration and improve their patients' quality of life...
February 2018: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/29610923/psoriasis
#19
Mark Lebwohl
Psoriasis, an inherited disorder of the immune system, presents most commonly in the skin and joints but is also associated with cardiovascular, metabolic, and neuropsychiatric effects. Treatments include topical therapy for mild disease; phototherapy and oral therapy, such as retinoids and immunomodulating agents; and targeted biologic therapies that have revolutionized treatment of psoriasis and psoriatic arthritis. Primary care physicians should be aware of the systemic associations of psoriasis and the treatments available for this disorder...
April 3, 2018: Annals of Internal Medicine
https://www.readbyqxmd.com/read/29599672/the-effect-of-subcutaneous-methotrexate-on-markers-of-metabolic-syndrome-in-psoriatic-patients-preliminary-report
#20
Agnieszka Owczarczyk-Saczonek, Marek Drozdowski, Agata Maciejewska-Radomska, Dariusz Choszcz, Waldemar Placek
Introduction: Methotrexate (MTX) has anti-proliferative and anti-inflammatory effects in psoriasis. Moreover, low doses can reduce the risk of developing cardiovascular diseases. It turns out that psoriasis and atherosclerosis have a similar pathogenetic mechanism: the same pro-inflammatory cytokines, Th1 and Th17, are involved in both diseases. Aim: To evaluate the effects of metabolic markers, protective cytokines (interleukin 10 (IL-10), transforming growth factor β (TGF-β)) and a marker of endothelial damage (endocan) in patients with plaque psoriasis...
February 2018: Postȩpy Dermatologii i Alergologii
keyword
keyword
77031
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"